Last updated 3 days ago

A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer

208 patients around the world

Available in United States, Brazil

This multicenter, open-label, Phase 1/2 study is designed to further characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary anti-tumor activity of IDE849, an anti-DLL3 antibody-drug conjugate, alone and in combination with durvalumab or IDE161, in subjects with DLL3-expressing tumors including small-cell lung cancer (SCLC), high-grade neuroendocrine carcinomas (NEC), and other DLL3-positive solid tumors. Part 1 (Dose Escalation): Part 1A will evaluate IDE849 monotherapy, and Part 1B will evaluate IDE849 in combination with durvalumab or IDE161. This phase is designed to assess safety and tolerability, identify dose-limiting toxicities (DLTs), and determine the maximum tolerated dose (MTD) and recommended dose for expansion (RDE), in subjects with extensive-stage SCLC, high-grade NEC, or other DLL3-expressing tumors. Part 2 (Dose Expansion): Part 2 further will evaluate IDE849 alone or in combination at selected dose levels to characterize safety, PK, immunogenicity, and preliminary anti-tumor activity in defined cohorts of subjects with extensive-stage SCLC, high-grade NEC, or other DLL3-expressing tumors.

IDEAYA Biosciences

3Research sites

208Patients around the world

This study is for people with

Lung cancer

Small cell lung carcinoma

Neuroendocrine Tumor

Requirements for the patient

From 18 Years

All Gender

Medical requirements

: Are willing to participate in this clinical study, understand the study procedures, and are able to sign the written ICF.
Subjects with histologically or cytologically confirmed extensive-stage SCLC neuroendocrine carcinoma (NEC), and other DLL3+ tumors, are eligible per protocol.
Subjects must have radiologically progressed or recurred after previous standard treatment.
For SCLC, this includes platinum-based therapy and programmed death-1/programmed death-ligand 1 inhibitors.
No more than 2 lines of previous systemic chemotherapy in any setting and no more than 3 total lines of systemic therapy in the recurrent or metastatic setting will be allowed.
Subjects will be required to provide blood/tumor tissue samples for biomarker testing.
Have at least 1 measurable lesion according to RECIST version 1.1.
Have Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.
Have life expectancy > 3 months.
Have adequate bone marrow and organ function.
Women of childbearing potential must agree to take highly effective contraceptive measures from signing of consent through 8 months after the last dose of IDE849.
Men with partners of child-bearing potential must use effective contraception through 5 months after the last dose.

: Have mixed SCLC and nonsmall cell lung cancer histology.
Subjects with locally untreated (radiotherapy or surgery) or active central nervous system (CNS) tumor metastasis.
Have had other malignancies within 2 years prior to the first dose, except adequately treated carcinoma in situ (cervical, breast, or other), basal cell or squamous cell skin cancer, localized prostate cancer after curative therapy with no recurrence, or papillary thyroid cancer after curative resection.
Other prior or concurrent malignancies may be eligible with Medical Monitor review and approval.
Have uncontrolled tumor-associated pain.
Have severe cardiovascular and cerebrovascular disease.
Have history of clinically significant bleeding within 3 months before the first study dose.
Have history of interstitial pneumonitis during previous treatment.
Current noninfectious pneumonitis requiring steroid therapy.
Known or suspected interstitial pneumonitis as seen on screening imaging.
Other moderate to severe lung diseases seriously affecting respiratory function within 3 months before the first dose, including, but not limited to, idiopathic pulmonary fibrosis and organizing pneumonia/obliterative bronchiolitis.
Have history of immunodeficiency, with a positive human immunodeficiency virus (HIV) test.
Subjects with known or suspected viral hepatitis.
Have a history of active tuberculosis within 1 year before enrollment.
For participants enrolling to receive the combination with durvalumab, must not have had any prior Grade 2 or higher myocarditis or any other Grade 3 or higher immune-related AE.
If the participant has had a prior immune-related AE, must have recovered to < Grade 1.
For participants enrolling to receive the combination with IDE161, must not have had prior gastrectomy or upper bowel removal or any other gastrointestinal disorder or defect eg, malabsorption disorder such as Crohn's disease or ulcerative colitis, that would interfere with absorption of IDE161.
Have received chemotherapy within 3 weeks of first dose of IMP.
Immunotherapy or biologic targeted anti-tumor treatments within 2 weeks before the first dose of IMP.
For small molecule treatments within 2 weeks before the first dose of the IMP or within 5 half lives of the drug (whichever is longer).
Other investigational products within 4 weeks or within 5 half-lives of the drug (whichever is longer) unless, in the opinion of the Investigator and Sponsor, the medication will not interfere with the study.
Participants who received an immunotherapy agent (eg, PD-1/PD-L1 inhibitor) immediately prior to study enrollment must have documented radiologic disease progression as per the Investigator prior to first dose of IMP.
Administration of any of the following.
Strong inhibitors or inducers of CYP3A4.
Strong inhibitors of CYP2D6.
Strong inhibitors of P-gp or BCRP.
For participants enrolling to receive the combination with IDE161.
Use of drugs of narrow therapeutic index that are sensitive substrates of MATE2-K, BCRP, and P-gp.
Use of known moderate and strong CYP3A4/5 inducers and inhibitors is not permitted.
Administration of PPIs.
Use of an H2 blocking agent.
Use of a local antacid.
Use of drugs with a known risk of QT prolongation.
Have prior treatment with DLL3 ADC or prior treatment with a topoisomerase I inhibitor including an ADC with a topoisomerase I inhibitor payload.
For participants enrolling to receive the combination with durvalumab, have history of prior intolerance to PD-1/PD-L1 inhibitors.
Have received > 30 Gy of chest radiotherapy within 12 weeks prior to the first dose of the IMP.
> 30 Gy of non-chest radiotherapy within 4 weeks prior to the first dose.
Subjects who have completed radiotherapy for brain metastases within 14 days prior to the first dose can be enrolled.
Palliative radiotherapy for other sites of ≤ 30 Gy is allowed if completed more than 14 days prior to the first dose.
Have undergone major surgery or experienced significant trauma within 4 weeks prior to the first dose.
Female subjects who are pregnant, lactating, or planning to become pregnant during the study period to 8 months after the last dose of the IMP.

Sites

Hospital de Câncer de Barretos - Fundação PIO XII

Rua Antenor Duarte Villela 1331 - Barretos, Sao Paulo, 14784-400

Hospital de Clínicas de Porto Alegre

Rua Ramiro Barcelos, 2350, Av. Protásio Alves, 211 - Santa Cecília, Porto Alegre - RS, 90035-903

Hospital De Base de São José do Rio Preto - CIP São José

Av. Brg. Faria Lima, 5544 - Vila Sao Jose, São José do Rio Preto - SP, 15090-000, Brazil

SponsorIDEAYA Biosciences

Study typeInterventional

Conditions

Small cell lung carcinomaNeuroendocrine Tumor

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT07174583